EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Para This, Fibromin That

Emad Ababneh, Vania Nosé

Clinics in Laboratory Medicine · 2026-09 · 46 (3) · 533-543

DOI: 10.1016/j.cll.2026.06.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinics in Laboratory Medicine, 2026-09. Verfasst von Emad Ababneh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Warren 214, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Pathology and Laboratory medicine Instit…. Hauptthemen laut MEDLINE: Tumor Suppressor Proteins, Parathyroid Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDC73 alterations are associated with three main parathyroid lesions according to the World Health Organization (WHO) classification of tumors of the endocrine system. These include hyperparathyroidism-jaw tumor (HPT-JT) syndrome-associated adenomas, atypical parathyroid tumors (APTs), and parathyroid carcinomas (PCs). The loss of nuclear parafibromin expression, which serves as a surrogate marker for the underlying CDC73 alteration, encompasses these tumors under the term parafibromin-deficient parathyroid tumors. They have distinct morphologic features of more abundant eosinophilic cytoplasm with perinuclear clearing surrounding a large nucleus as well as prominent dilated branching "hemangiopericytoma-like" vasculature and a thick capsule as well as variably sized cystic spaces. These tumors include cases that show unequivocal histologic features fulfilling the criteria for PCs with growing data indicating a higher rate of recurrence or metastasis compared with parafibromin intact PCs. More importantly, the loss of parafibromin expression can be used in clinical practice to recognize APTs that fall short of a conclusive diagnosis of PCs, but clinically behave akin to them. Moreover, recognizing these tumors can lead to an underlying germline mutation and a diagnosis of HPT-JT, which impacts long-term treatment and surveillance for patients and close family.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor ProteinsParathyroid NeoplasmsNeoplastic Syndromes, HereditaryHumans

Stichwörter der Autor:innen

CDC73HPT-JT syndromeHyperparathyroidismParafibrominParafibromin-deficient parathyroid tumorParathyroidParathyroid carcinoma

Substanzen

CDC73 protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Pathology, Warren 214, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Pathology and Laboratory medicine Institute, L25, Cleveland Clinic foundation, 9500 Euclid Avenue, Cleveland,…
  • Department of Pathology, Warren 214, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: vnose@mgh.harvard.edu.

Zitieren

APA

Ababneh, E., & Nosé, V. (2026). Para This, Fibromin That. Clinics in Laboratory Medicine, 46(3), 533-543. https://doi.org/10.1016/j.cll.2026.06.008

Vancouver

Ababneh E, Nosé V. Para This, Fibromin That. Clinics in Laboratory Medicine. 2026;46(3):533-543. doi:10.1016/j.cll.2026.06.008

BibTeX
@article{Ababneh2026,
  author = {Ababneh, Emad and Nosé, Vania},
  title = {Para This, Fibromin That},
  journal = {Clinics in Laboratory Medicine},
  year = {2026},
  volume = {46},
  number = {3},
  pages = {533--543},
  doi = {10.1016/j.cll.2026.06.008}
}
Kostenlos starten →